Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT	OF CHANGE	S IN BENEF	ICIAL O	WNERSHIP
• .,	0. 0	• <b>==</b>		

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     ENGLEMAN EDGAR					2. Issuer Name and Ticker or Trading Symbol Eiger BioPharmaceuticals, Inc. [ EIGR ]					(Ch	Relationship $\mathfrak{g}$ eck all application $\mathfrak{g}$	cable)	g Pers	. ,			
(Last) 575 HIG	`	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/28/2016								Officer (give title Other (spe below) below)				
(Street) PALO A (City)	LTO C	A	94301 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	dividual or Joint/Group Filing (Check Applicable )  Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Tab	le I - Non-	Derivativ	e Se	curities	s Ac	quired, D	sposed o	of, or Be	neficial	y Owned	l				
Date			2. Transactio Date Month/Day/Y	Execution Date,		Code (Instr. 5)		ed (A) or tr. 3, 4 and	Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)				
					Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a								
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)		Code	Transaction of Code (Instr. Derivative		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to	\$15.75	03/28/2016		A	v	25,000		(1)(2)	03/28/2026	Common Stock	25,000	\$0.00	25,000	)	D		

## Explanation of Responses:

- 1. The option vests in equal monthly installments over 12 months measured from March 28, 2016 subject to Reporting Person's continuous service status as of each such date.
- 2. The option is subject to shareholder approval of an amendment to the Celladon Corporation 2013 Equity Incentive Plan. This is a voluntary early filing.

## Remarks:

/s/ Edgar Engleman 03/28/2016

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.